TL;DR
This study investigated how anatomical changes during radiation therapy for virally mediated head and neck cancers (VMHNC) affect radiation dose distribution. They found that while target tumor doses remained largely unaffected, critical organs at risk (OARs) received higher doses, potentially increasing side effects. This highlights the need for adaptive radiotherapy strategies, especially with advanced techniques like IMRT.
What Problem Does This Paper Address?
Head and neck cancer patients, particularly those with virally mediated cancers (like HPV-related oropharyngeal cancer), often experience significant anatomical changes during radiation therapy. These changes can include tumor and nodal shrinkage, as well as patient weight loss. These shifts can alter the planned radiation dose distribution, potentially leading to underdosing of the tumor (reducing treatment effectiveness) or overdosing of surrounding healthy tissues (increasing the risk of acute and long-term side effects). This is especially critical with modern, highly conformal radiation techniques like Intensity-Modulated Radiation Therapy (IMRT), which rely on steep dose gradients. The paper aims to quantify the dosimetric impact of these anatomical changes in VMHNC patients to inform the development of better adaptive radiotherapy strategies.
Methods
The researchers conducted a retrospective study on 13 patients with virally mediated oropharyngeal or nasopharyngeal cancer who underwent definitive radiotherapy between 2005 and 2010 and required a replan due to anatomical changes. They compared the original treatment plan (based on the initial planning CT) with a "comparison plan" calculated on a repeat CT (re-CT) taken later in the treatment course. This comparison plan used the same treatment fields and monitor units as the original plan, but was recalculated on the re-CT data to isolate the dosimetric effect of anatomical changes.
Key techniques included:
- Re-contouring: A radiation oncologist re-contoured the gross target volumes (GTVs) for the primary tumor (GTV-p) and nodes (GTV-n), as well as organs at risk (OARs) like the spinal cord, brainstem, and parotid glands, on both the planning CT and the re-CT.
- Dose-Volume Histogram (DVH) Analysis: DVHs were generated for both the original and comparison plans to quantify the dose delivered to the target volumes and OARs.
- Volumetric Analysis: Changes in the volume of GTVs and OARs were measured between the planning CT and re-CT.
- Statistical Analysis: Mann-Whitney and Wilcoxon tests were used to analyze differences in volume and dose, with a P-value of <0.05 considered statistically significant.
Datasets
The study utilized data from 13 patients treated at the Princess Alexandra Hospital (PAH) between 2005 and 2010. Patient data included demographics, tumor characteristics (site, stage, HPV/EBV status), smoking history, nodal size, treatment technique (3DCRT or IMRT), and weight measurements at planning and re-CT. The primary data for dosimetric evaluation came from the treatment planning system's CT scans and associated treatment plans. No new datasets or benchmarks were introduced.
Key Insights and Ideas
- OARs are the primary concern: The most significant dosimetric impact of anatomical changes was observed in organs at risk (OARs), not the target tumors. This is a critical finding because exceeding OAR tolerance doses can lead to severe, permanent side effects.
- VMHNC patients are unique: These patients often present with more responsive disease and a better prognosis, making the minimization of long-term side effects a paramount goal. This underscores the importance of addressing anatomical changes.
- IMRT's sensitivity: Advanced techniques like IMRT, while offering precise dose delivery, create steep dose gradients. This makes them more susceptible to the negative effects of anatomical shifts, potentially leading to both under- and overdosing.
- Weight loss is a major driver: Patient weight loss was a significant factor contributing to anatomical changes, impacting both target volumes and OARs.
Key Results
- Target Volume Dose: The mean dose to 98% of the primary gross tumor volume (GTV-p) and nodal gross tumor volume (GTV-n) slightly decreased (by 0.15% and 0.3%, respectively) when comparing the primary plan to the comparison plan. These changes were not statistically significant.
- OAR Dose:
- The spinal cord dose increased by an average of 4.1%.
- The brainstem dose increased by an average of 2.6%.
- The mean dose to the parotid glands increased by an average of 3.5%.
- Eleven out of thirteen patients (84.6%) experienced an increase in dose to two or more OARs.
- Volume Changes:
- All patients experienced weight loss (mean 6.5%).
- Significant volume reductions were observed in GTV-n (mean 50.8%) and GTV-p (mean 30%), though these did not reach statistical significance (P=0.09 and P=0.06, respectively).
- Parotid gland volumes also decreased significantly (left: 21.8%, right: 26.4%).
- Individual Patient Variability: One patient showed a minimal change in target volume dose but a substantial increase in OAR doses (4.2% for spinal cord, 13.4% and 8% for parotid glands), illustrating the potential for significant individual impact.
Limitations and Future Work
- Limitations:
- Small Sample Size: The study included only 13 patients, which may have limited its power to detect statistically significant differences.
- Retrospective Nature: The retrospective design means a lack of control over data consistency and the timing of events.
- Re-CT Timing: Re-CTs were performed after anatomical changes were observed by staff, not at precisely determined time points, limiting the ability to pinpoint the exact moment of dosimetric impact.
- Contouring Variability: Variability in contouring between the planning CT and re-CT by different oncologists could have influenced the results.
- Daily Imaging Not Used: The absence of daily volumetric imaging prevented a precise assessment of the timing and extent of anatomical changes.
- Future Work:
- The authors propose testing adaptive radiotherapy protocols in conjunction with daily image guidance to precisely determine the timing of anatomical changes and their dosimetric impact.
- They suggest a larger prospective study, including all head and neck cancer patients (stratified by VMHNC status), to further investigate these findings.
- The study's findings provide baseline data for developing more effective adaptive treatment strategies.
Summary updated